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Outcome URD-T
(n ¼ 153)
DCB-T
(n ¼ 58)
P Value
3-year TRM 25% (95%CI: 18-33) 22% (95%CI: 13-34) 0.860
3-year Relapse 22% (95%CI: 16-29) 7% (95%CI: 2-17) 0.009
3-year DFS 53% (95%CI: 45-62) 70% (95%CI: 59-83) 0.080
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protection against relapse. However, given there are no
randomized trials comparing survival after URD-T and DCB-T,
this question is a subject of ongoing controversy.
Methods: We evaluated 211 consecutive adult allograft
recipients (153 URD-T and 58 DCB-T) aged 16-60 years
transplanted 10/2005-12/2012 for acute leukemia in
morphologic remission (115 AML/ biphenotypic, 52 ALL),
MDS with 5% bone marrow blasts at work-up (n ¼ 32), or
advanced CML (n ¼ 12). URD were 8-10/10 HLA-matched
(89 10/10, 52 9/10, 12 8/10). CB grafts were 4-6/6 donor-
recipient HLA-matched (6 6/6, 53 5/6, 57 4/6). All patients
received either myeloablative or reduced intensity condi-
tioning. GVHD prophylaxis was calcineurin-inhibitor/MMF
based in DCB-T recipients whereas the majority of URD-T
recipients (n ¼ 138, 90%) received T-cell depleted (TCD)
grafts.
Results: The median ages of URD-T (46 years) and DCB-T
(42 years) recipients were similar (p ¼ 0.22) and distri-
bution of diagnoses was also similar. Neutrophil engraft-
ment was inferior in DCB-T (95%, median 24 days) as
compared to URD-T (100%, median 11 days) recipients
(p <0.001), and GVHD rates were signiﬁcantly higher in
DCB-T as compared to TCD URD-T recipients (data not
shown). Survival end-points are shown in the Table. The
median (range) follow-up of survivors are similar in URD-
T (46 months, 9-96) and DCB-T (42 months, 11-88) groups.
While the 6-month transplant-related mortality (TRM)
was higher in DCB-T (21%) versus URD-T (8%) recipients,
the 3-year TRM were similar (p ¼ 0.860). Moreover, the
3-year relapse risk was signiﬁcantly decreased in DCB-T
recipients (7%, p ¼ 0.009). DCB-T recipients had a 70%
3-year DFS (p ¼ 0.08, Figure).
Conclusions: These results provide highly encouraging
preliminary data. In the absence of a large randomized trialin adult patients which will be extremely challenging to
conduct in the U.S., further investigation of larger patient
populations controlled for possible confounding factors is
needed. However, in the interim, this data supports DCB-T
(performed in centers with a strong interest in the optimal
conduct of CB-T) as an immediate alternative to URD-T given
the strong protection against relapse in patients with acute
leukemia and other high-risk myeloid malignancies such as
CML and MDS.58
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Introduction: Criteria for selecting cord blood (CB) units
with high engraftment potential are not established.
Methods: We investigated the donor variables associated
with neutrophil engraftment in recipients of myeloablative
double-unit CB transplantation at our transplant center (TC)
and then evaluated whether these unit characteristics could
be reliably determined at the time of unit selection in 402 CB
units thawed at our TC from 10/2005-06/2013.
Results: The cumulative incidence of neutrophil engraft-
ment in 130 recipients was 95% (95%CI: 90-98). In multi-
variate analysis, only the dominant unit infused viable
CD34+ cell dose/kg independently inﬂuenced engraftment
[HR 1.95, p ¼ 0.001] (Figure). We then analyzed the
components of infused viable CD34+ cell dose (i.e. post-
thaw CD34+ cell count and percent viability) in 402 units
(302 domestic and 100 international) from 43 Banks thawed
at our TC. Bank CD34+ cell count correlated with post-thaw
measurements (r2 ¼ 0.6, p < 0.001). The median CD34+ cell
recovery was 101% but ranged 12-1480%. Recovery < 65%
occurred less frequently in units from FACT-accredited
Banks. Moreover, while the median post-thaw CD34+ cell
viability was 92%, 33 (8%) units had < 75% viable CD34+
cells post-thaw. Bank FACT accreditation and CB unit
cryovolume were signiﬁcantly associated with post-thaw
viability (Table). Bank location (all domestic vs. all interna-
tional), shipping distance (local vs. distant international)
and duration of cryopreservation were not associated with
viability.
Conclusion: Infused viable CD34+ cell dose was the critical
determinant of engraftment, and CD34+ cell count recovery
and viability were linked to differences in banking practices.
These ﬁndings have signiﬁcant implications for banking and
CB unit selection. At our TC, we now prioritize standard
25ml units from FACT-accredited banks and strongly
consider the CD34+ cell dose. However, with such a practice,
TC must be able to react to lower than expected post-thaw
CD34+ cell counts and/or low CD34+ cell viability. This
requires measurement of the infused viable CD34+ cell dose
(or another rapidly available measure of potency) on
transplant day and a back-up strategy in case of a
compromised unit. This is even more critical in single-unit
CBT in which engraftment is solely dependent on a single
unit.
Figure. Neutrophil engraftment by dominant unit infused viable CD34+ cell dose 105/kg
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Background: High-dose chemotherapy followed by autolo-
gous stem cell transplantation (ASCT) for multiple myeloma
(MM) offers a unique opportunity for the early introduction of
consolidative immunotherapy to improve patient outcomes.
Post-transplant reconstitution of immune cell subsets, how-
ever, occurs with disparate kinetics that can affect efﬁcacy. A
comprehensive understanding of the immunologic milieu is
therefore essential to the rational development of immuno-
therapeutic interventions after ASCT, where relapse remains
the primary cause of treatment failure.
Methods: Immune reconstitution in 40 MM patients un-
dergoing ASCT was evaluated for one year. Peripheral blood
